Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., Dummer, R.Volume:
18
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-11-1491
Date:
January, 2012
File:
PDF, 374 KB
english, 2012